Cian Stutz

Title: Cian Stutz: Innovator in Bispecific Antibodies

Introduction

Cian Stutz is a prominent inventor based in La Chaux-de-Fonds, Switzerland. He has made significant contributions to the field of immunology, particularly through his innovative work on bispecific antibodies. His research focuses on developing novel therapeutic solutions for autoimmune and proliferative diseases.

Latest Patents

Cian Stutz holds 1 patent for his invention titled "CD47-CD38 bispecific antibodies." This patent describes a new class of bispecific heterodimeric immunoglobulins that target both the human CD47 antigen and the human CD38 antigen. The invention includes antibodies that comprise an anti-CD38 heavy chain variable region and a light chain variable region, as well as an anti-CD47 heavy chain variable region and a light chain variable region. The application of these bispecific antibodies is particularly relevant for treating various cancers, including hematologic malignancies and solid tumors.

Career Highlights

Cian Stutz is currently associated with Igi Therapeutics SA, where he continues to advance his research in immunotherapy. His work is pivotal in the development of new treatment modalities that can potentially improve patient outcomes in oncology.

Collaborations

Cian collaborates with talented professionals in his field, including Laure Bouchez and Blandine Pouleau. Their combined expertise contributes to the innovative research environment at Igi Therapeutics SA.

Conclusion

Cian Stutz is a key figure in the development of bispecific antibodies, with a focus on addressing critical health challenges in cancer treatment. His contributions to immunology are paving the way for future advancements in therapeutic strategies.